The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1211
June 20, 2005
View Complete Issue         Table of Contents 2019 
Micafungin (Mycamine) for Fungal Infections
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Micafungin (Mycamine) for Fungal Infections
June 20, 2005 (Issue: 1211)
Micafungin sodium (Mycamine - Astellas), the second echinocandin antifungal to become available in the US, has been approved by the FDA for intravenous treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Micafungin (Mycamine) for Fungal Infections
Article code: 1211c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.